Classical Hodgkin Lymphoma Today

Mediterr J Hematol Infect Dis. 2026 Jul 1;18(1):e2026055. doi: 10.4084/MJHID.2026.055. eCollection 2026.ABSTRACTClassical Hodgkin Lymphoma is one of the most curable neoplasms worldwide, particularly among young adults. Significant advances have been made to maximize treatment efficacy and minimize

F Francesco D'Alò

Impact of endovascular revascularization, pharmacotherapy, and supervised exercise therapy on long-term cardiovascular, cerebrovascular, mortality, and limb outcomes in patients with peripheral artery disease: a systematic review and network meta-analysis

Front Med (Lausanne). 2026 Jul 1;13:1874951. doi: 10.3389/fmed.2026.1874951. eCollection 2026.ABSTRACTOBJECTIVE: This systematic review and network meta-analysis compared the long-term effects of endovascular reconstruction/revascularization (ER), supervised exercise therapy (SET), medical therapy (

J Jiayue Feng

Association between Chinese herbal medicine and the composite outcome of repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: a prospective cohort study

J Geriatr Cardiol. 2026 Jun 28;23(6):333-343. doi: 10.26599/1671-5411.2026.06.003.ABSTRACTOBJECTIVE: To evaluate the association between adjunctive Chinese herbal medicine (CHM) and post-percutaneous coronary intervention (PCI) adverse cardiovascular events in patients with chronic coronary syndrome

X Xiao-Di Ji

Microprotein, macro-effect: DWORF as a therapeutic strategy in heart failure

Front Cell Dev Biol. 2026 Jul 1;14:1864847. doi: 10.3389/fcell.2026.1864847. eCollection 2026.ABSTRACTHeart failure (HF) is a global health crisis and remains a leading cause of morbidity, mortality, and healthcare expenditure despite substantial advances in pharmacological and device-based therapy.

J Joseph P Verry